Velcade Patent Ruling Puts More Pressure On Ixazomib Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
District court finds formulation patent covering Takeda’s top drug is obvious in light of prior art, opening product up to generic competition in 2017.
You may also be interested in...
Takeda’s Global Ambitions Focus On Crohn’s, Cancer – And Churn
Three product launches in U.S. last year, including Entyvio, showcase its expansion strategy, but first non-Japanese CEO could be biggest shift for firm.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.